Eisai
Eisai poaches senior Pfizer and Sanofi execs for neurology group
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim
Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
Eisai’s Halaven recommended for European approval
April 4, 2016Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma
Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
Eisai announces agreement to set up new gastrointestinal speciality company
March 30, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality
Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …
Eisai withdraws application for neurodegenerative-disease drug in Japan
March 22, 2016Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease
Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …
Eisai slams new Cancer Drugs Fund for delaying patient access
February 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima
Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …
FDA grants Eisai’s Lenvima priority review for kidney cancer
January 19, 2016Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma
The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …
Eisai submits new cancer combo to EMA for approval
January 12, 2016Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib
Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …
Eisai’s Halaven shown to restrict further cancer metastasis
December 11, 2015Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda
New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
Eisai earns FDA nod for Fycompa
June 22, 2015Sales and Marketing Eisai, FDA, Fycompa
The FDA has expanded the patient groups for whom Eisai’s epilepsy drug Fycompa is available to include people who have …
Eisai seeks new ALS drug approval
May 28, 2015Sales and Marketing Eisai, Japan, als, mecobalamin
Eisai is hoping that existing neurology drug mecobalamin can be a new option for the difficult-to-treat condition amyotrophic lateral sclerosis …
Eisai epilepsy drug sees EMA nod
May 27, 2015Research and Development, Sales and Marketing Eisai, Fycompa, ema. epilepsy
Eisai’s UK subsidiary has received a positive opinion from the European Medicines Agency for using Fycompa for the adjunctive treatment …
Bayer wins Cancer Drugs Fund appeal
May 22, 2015Sales and Marketing Bayer, CDF, Cancer Drugs Fund, Eisai, NHS, lilly
Bayer is the only company to win its appeal to NHS England in the latest round of Cancer Drugs Fund …
Eisai cuts 25% of US staff
April 10, 2015Medical Communications, Research and Development, Sales and Marketing Daiichi, Eisai, US, cuts, layoffs, reorganisation, staff
Eisai’s US business is offloading around 200 jobs as part of some restructuring to create a more ‘efficient and focussed …
EMA committee recommends five drugs for approval
March 30, 2015Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly
Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …
Eisai Alzheimer’s drug to see China review
March 4, 2015Sales and Marketing Alzheimer's, Aricept, China, Eisai, donepezil hydrochloride
Alzheimer’s drug Aricept from Eisai has been accepted for review in China to treat patients with the most severe form …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
